Minnesota FOIA #P009203901

Amyloid beta peptides and type-2 diabetes sequelae synergistically inhibit insulin signaling and trafficking at the b...

This purchase order is a contract awarded on June 23, 2022, by the Twin Cities government entity to Mayo Clinic, located in Minneapolis, Minnesota, USA. The contract involves a research project focused on amyloid beta peptides and type-2 diabetes sequelae, with an obligated and award amount of $621,618. The vendor, Mayo Clinic, is a major medical research institution. The purchase includes a single line item describing the research focus, with no specific product or service details beyond the research description. The contract appears to be a single-transaction award for a research study, possibly a multi-year project. The award is categorized under the 'state' government sector due to the Twin Cities jurisdiction, with the location specified as Minneapolis, MN. The primary NAICS code relevant to research and medical services is 541712 (Research and Development in Biotechnology).

Description

Amyloid beta peptides and type-2 diabetes sequelae synergistically inhibit insulin signaling and trafficking at the blood brain barrier